Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
short bowel syndrome
Biotech
Ironwood makes further bid for $1B GI drug with subgroup data
On the heels of a phase 3 win that failed to impress investors, Ironwood is back to say its treatment is consistent across baseline demographics.
Gabrielle Masson
Oct 28, 2024 12:33pm
Ironwood seeing STARS as phase 3 hit triggers 30% stock drop
Feb 29, 2024 7:52am
Ironwood pays $1B for VectivBio and its phase 3 GI drug
May 22, 2023 10:05am
Zealand rival to Takeda bowel disease drug hits goal in phase 3
Sep 30, 2022 9:00am
Rare disease startup Therachon nets GLyPharma and its SBS drug
Oct 9, 2018 10:23am
Sanofi partner Zealand files for IPO to fund drug approvals
Jul 7, 2017 7:01am
